Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section
|
|
- Maximilian Carroll
- 5 years ago
- Views:
Transcription
1 Report generated from BNF provided by FormularyComplete ( Accessed Title Formulary Status Section TA Number TA Link Annotation ACICLOVIR Aciclovir 5.3 Antiviral drugs->5.3.2 Herpesvirus infections-> Herpes simplex and varicella zoster infection 5.3 Antiviral drugs->5.3.2 Herpesvirus infections-> Herpes simplex and varicella zoster infection->aciclovir Aminoglycosides 5.1 Antibacterial drugs Amoebicides 5.4 Antiprotozoal drugs AMOXICILLIN Amoxicillin Amoxil Ancotil Anthelmintics Antibacterial drugs Antifungal drugs 5.1 Antibacterial drugs->5.1.1 Penicillins-> Broad-spectrum penicillins 5.1 Antibacterial drugs->5.1.1 Penicillins-> Broad-spectrum penicillins->amoxicillin 5.1 Antibacterial drugs->5.1.1 Penicillins-> Broad-spectrum penicillins->amoxicillin 5.2 Antifungal drugs->5.2.5 Other antifungals->flucytosine Antimalarials 5.4 Antiprotozoal drugs Antiprotozoal drugs Antipseudomonal penicillins 5.1 Antibacterial drugs->5.1.1 Penicillins Antituberculosis drugs 5.1 Antibacterial drugs Antiviral drugs Atripla reverse transcriptase inhibitors->tenofovir DISOPROXIL->With efavirenz and emtricitabine
2 Augmentin 5.1 Antibacterial drugs->5.1.1 Penicillins-> Broad-spectrum penicillins->co-amoxiclav Recommendation to use 1 x co-amoxiclav 250/125 and 1 x amoxicillin 250 mg in place of 1 x co-amoxiclav 500/125 tablet approved by D& T committee (11/07/05). Benzylpenicillin and phenoxymethylpenicillin 5.1 Antibacterial drugs->5.1.1 Penicillins BENZYLPENICILLIN SODIUM 5.1 Antibacterial drugs->5.1.1 Penicillins-> Benzylpenicillin and phenoxymethylpenicillin BOCEPREVIR Chronic hepatitis C TA253 PAH Trust does not comission the service requiring use of this drug. Broad-spectrum penicillins 5.1 Antibacterial drugs->5.1.1 Penicillins CEFALEXIN Cefalexin CEFRADINE CEFUROXIME Cephalosporins Cephalosporins, carbapenems, and other beta-lactams Ceporex Cephalosporins Cephalosporins->CEFALEXIN Cephalosporins Cephalosporins carbapenems, and other beta-lactams 5.1 Antibacterial drugs Cephalosporins->CEFALEXIN Chloroquine 5.4 Antiprotozoal drugs->5.4.1 Antimalarials CHLOROQUINE 5.4 Antiprotozoal drugs->5.4.1 Antimalarials->Chloroquine Cidomycin 5.1 Antibacterial drugs->5.1.4 Aminoglycosides->GENTAMICIN See Trust Antibiotic Policy for futher details on clinical use. Please refer to Modified Once Daily Gentamicin regime in adults: PAH Trust Guidelines.
3 CLARITHROMYCIN 5.1 Antibacterial drugs->5.1.5 Macrolides Clindamycin 5.1 Antibacterial drugs CLINDAMYCIN 5.1 Antibacterial drugs->5.1.6 Clindamycin Clindamycin 5.1 Antibacterial drugs->5.1.6 Clindamycin->CLINDAMYCIN CO-AMOXICLAV 5.1 Antibacterial drugs->5.1.1 Penicillins-> Broad-spectrum penicillins Recommendation to use 1 x co-amoxiclav 250/125 and 1 x amoxicillin 250 mg in place of 1 x co-amoxiclav 500/125 approved by D& T Committee (11/07/05). Co-amoxiclav 5.1 Antibacterial drugs->5.1.1 Penicillins-> Broad-spectrum penicillins->co-amoxiclav Recommendation to use 1 x co-amoxiclav 250/125 and 1 x amoxicillin 250 mg in place of 1 x co-amoxiclav 500/125 approved by D&T committee (11/07/05). COLISTIMETHATE SODIUM antibacterials->polymyxins TA276 Colistimethate sodium antibacterials->polymyxins->colistimethate SODIUM Colobreathe antibacterials->polymyxins->colistimethate SODIUM Copegus 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus->ribavirin This drug is not used by the Trust as we do not provide services requiring its use. Crystapen 5.1 Antibacterial drugs->5.1.1 Penicillins-> Benzylpenicillin and phenoxymethylpenicillin->benzylpenicillin SODIUM DACLATASVIR Chronic hepatitis C Daklinza Chronic hepatitis C->DACLATASVIR Dalacin C 5.1 Antibacterial drugs->5.1.6 Clindamycin->CLINDAMYCIN Dificlir antibacterials->fidaxomicin->fidaxomicin For treating recurrent Clostridium difficile infection on approval of a consultant microbiologist only. DOXYCYCLINE 5.1 Antibacterial drugs->5.1.3 Tetracyclines See Trust Antibiotic Policy Doxycycline 5.1 Antibacterial drugs->5.1.3 Tetracyclines->DOXYCYCLINE See Trust Antibiotic Policy
4 Drugs for threadworms 5.5 Anthelmintics ENTECAVIR 5.3 Antiviral drugs->5.3.3 Viral hepatitis-> Chronic hepatitis B TA153 Not stocked in pharmacy as PAH does not comission the service requiring use of this drug. Erythrocin 5.1 Antibacterial drugs->5.1.5 Macrolides->ERYTHROMYCIN ERYTHROMYCIN 5.1 Antibacterial drugs->5.1.5 Macrolides Erythromycin 5.1 Antibacterial drugs->5.1.5 Macrolides->ERYTHROMYCIN Erythromycin Ethyl Succinate 5.1 Antibacterial drugs->5.1.5 Macrolides->ERYTHROMYCIN Erythromycin Lactobionate 5.1 Antibacterial drugs->5.1.5 Macrolides->ERYTHROMYCIN FIDAXOMICIN antibacterials->fidaxomicin For treating recurrent Clostridium difficile infection on approval of a consultant microbiologist only. Flagyl 5.1 Antibacterial drugs-> Metronidazole and tinidazole->metronidazole FLUCLOXACILLIN 5.1 Antibacterial drugs->5.1.1 Penicillins-> Penicillinase-resistant penicillins Flucloxacillin 5.1 Antibacterial drugs->5.1.1 Penicillins-> Penicillinase-resistant penicillins->flucloxacillin FLUCYTOSINE 5.2 Antifungal drugs->5.2.5 Other antifungals Fucidin Fusidic acid antibacterials->fusidic acid->sodium FUSIDATE antibacterials GENTAMICIN 5.1 Antibacterial drugs->5.1.4 Aminoglycosides See Trust Antibiotic Policy for futher details on clinical use. Please refer to Modified Once Daily Gentamicin regime in adults: PAH Trust Guidelines. Gentamicin 5.1 Antibacterial drugs->5.1.4 Aminoglycosides->GENTAMICIN See Trust Antibiotic Policy for futher details on clinical use. Please refer to Modified Once Daily Gentamicin regime in adults: PAH Trust Guidelines. Genticin 5.1 Antibacterial drugs->5.1.4 Aminoglycosides->GENTAMICIN Glycopeptides antibacterials
5 GRISEOFULVIN 5.2 Antifungal drugs->5.2.5 Other antifungals Griseofulvin 5.2 Antifungal drugs->5.2.5 Other antifungals->griseofulvin HIV infection 5.3 Antiviral drugs Incivo Chronic hepatitis C->TELAPREVIR ISONIAZID drugs Isoniazid drugs->isoniazid ITRACONAZOLE 5.2 Antifungal drugs->5.2.1 Triazole antifungals Keflex Kemicetine Klaricid Lipid formulations Cephalosporins->CEFALEXIN antibacterials->chloramphenicol->chloramphenicol 5.1 Antibacterial drugs->5.1.5 Macrolides->CLARITHROMYCIN 5.2 Antifungal drugs->5.2.3 Polyene antifungals->amphotericin Macrolides 5.1 Antibacterial drugs MEBENDAZOLE 5.5 Anthelmintics->5.5.1 Drugs for threadworms Metrolyl METRONIDAZOLE Metronidazole 5.1 Antibacterial drugs-> Metronidazole and tinidazole->metronidazole 5.1 Antibacterial drugs-> Metronidazole and tinidazole 5.1 Antibacterial drugs-> Metronidazole and tinidazole->metronidazole METRONIDAZOLE 5.4 Antiprotozoal drugs->5.4.2 Amoebicides Metronidazole and tinidazole 5.1 Antibacterial drugs NITROFURANTOIN 5.1 Antibacterial drugs-> Urinary-tract infections
6 Nitrofurantoin Olysio 5.1 Antibacterial drugs-> Urinary-tract infections->nitrofurantoin Chronic hepatitis C->SIMEPREVIR OSELTAMIVIR 5.3 Antiviral drugs->5.3.4 Influenza TA168 OSELTAMIVIR 5.3 Antiviral drugs->5.3.4 Influenza TA158 Other antifungals 5.2 Antifungal drugs OXYTETRACYCLINE 5.1 Antibacterial drugs->5.1.3 Tetracyclines Oxytetracycline Penicillinase-resistant penicillins 5.1 Antibacterial drugs->5.1.3 Tetracyclines->OXYTETRACYCLINE 5.1 Antibacterial drugs->5.1.1 Penicillins Penicillins 5.1 Antibacterial drugs PHENOXYMETHYLPENICILLIN Phenoxymethylpenicillin 5.1 Antibacterial drugs->5.1.1 Penicillins-> Benzylpenicillin and phenoxymethylpenicillin 5.1 Antibacterial drugs->5.1.1 Penicillins-> Benzylpenicillin and phenoxymethylpenicillin->phenoxymethylpenicillin Polyene antifungals 5.2 Antifungal drugs Polymyxins antibacterials Primaquine 5.4 Antiprotozoal drugs->5.4.1 Antimalarials PRIMAQUINE 5.4 Antiprotozoal drugs->5.4.1 Antimalarials->Primaquine Proguanil 5.4 Antiprotozoal drugs->5.4.1 Antimalarials PROGUANIL HYDROCHLORIDE PROGUANIL HYDROCHLORIDE WITH ATOVAQUONE 5.4 Antiprotozoal drugs->5.4.1 Antimalarials->Proguanil 5.4 Antiprotozoal drugs->5.4.1 Antimalarials->Proguanil Quinine 5.4 Antiprotozoal drugs->5.4.1 Antimalarials QUININE 5.4 Antiprotozoal drugs->5.4.1 Antimalarials->Quinine
7 Quinolones 5.1 Antibacterial drugs Respiratory syncytial virus 5.3 Antiviral drugs RIBAVIRIN 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus TA331 This drug is not used by the Trust as we do not provide services requiring its use. RIBAVIRIN 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus TA200 This drug is not used by the Trust as we do not provide services requiring its use. RIBAVIRIN 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus TA200 This drug is not used by the Trust as we do not provide services requiring its use. Rifater drugs->rifampicin->combined preparations Rifaximin antibacterials RIFAXIMIN antibacterials->rifaximin TA337 SIMEPREVIR Chronic hepatitis C TA331 SODIUM FUSIDATE antibacterials->fusidic acid SOFOSBUVIR Chronic hepatitis C TA330 SOFOSBUVIR Chronic hepatitis C TA330 Sovaldi Chronic hepatitis C->SOFOSBUVIR Sporanox 5.2 Antifungal drugs->5.2.1 Triazole antifungals->itraconazole STREPTOMYCIN drugs Streptomycin Sulfate Sulfonamides and trimethoprim drugs->streptomycin 5.1 Antibacterial drugs Tamiflu 5.3 Antiviral drugs->5.3.4 Influenza->OSELTAMIVIR Targaxan antibacterials->rifaximin->rifaximin
8 TELAPREVIR Chronic hepatitis C TA252 NICE TA 252 Hepatitis C (genotype 1) - PAH Trust does not comission the service requiring use of this drug TENOFOVIR DISOPROXIL reverse transcriptase inhibitors TA173 TETRACYCLINE 5.1 Antibacterial drugs->5.1.3 Tetracyclines Tetracyclines 5.1 Antibacterial drugs TRIMETHOPRIM Truvada 5.1 Antibacterial drugs->5.1.8 Sulfonamides and trimethoprim reverse transcriptase inhibitors->tenofovir DISOPROXIL->With emtricitabine Urinary-tract infections 5.1 Antibacterial drugs VALACICLOVIR Valtrex Vermox Victrelis Virazole Viread With efavirenz and emtricitabine With emtricitabine 5.3 Antiviral drugs->5.3.2 Herpesvirus infections-> Herpes simplex and varicella zoster infection 5.3 Antiviral drugs->5.3.2 Herpesvirus infections-> Herpes simplex and varicella zoster infection->valaciclovir 5.5 Anthelmintics->5.5.1 Drugs for threadworms->mebendazole Chronic hepatitis C->BOCEPREVIR 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus->ribavirin reverse transcriptase inhibitors->tenofovir DISOPROXIL reverse transcriptase inhibitors->tenofovir DISOPROXIL reverse transcriptase inhibitors->tenofovir DISOPROXIL ZANAMIVIR 5.3 Antiviral drugs->5.3.4 Influenza TA168
9 ZANAMIVIR 5.3 Antiviral drugs->5.3.4 Influenza TA158 Zovirax 5.3 Antiviral drugs->5.3.2 Herpesvirus infections-> Herpes simplex and varicella zoster infection->aciclovir ABACAVIR reverse transcriptase inhibitors AmBisome 5.2 Antifungal drugs->5.2.3 Polyene antifungals->amphotericin->lipid formulations Liposomal Amphoteracin (Ambisome)to be used in accordance with the febrile neutopenia guideline (DA-005)or as recommended by a haematologist/microbiologist. AMPHOTERICIN 5.2 Antifungal drugs->5.2.3 Polyene antifungals AZITHROMYCIN 5.1 Antibacterial drugs->5.1.5 Macrolides Liposomal Amphoteracin (Ambisome)to be used in accordance with the febrile neutopenia guideline (DA-005)or as recommended by a haematologist/microbiologist. Consultant signature only for Bronchiectasis and Cystic fibrosis patients. Also for DOSH in accordance with guidelines. Azithromycin 5.1 Antibacterial drugs->5.1.5 Macrolides->AZITHROMYCIN Consultant signature only for Bronchiectasis and Cystic fibrosis patients. Also for DOSH in accordance with guidelines. Cancidas 5.2 Antifungal drugs->5.2.4 Echinocandin antifungals->caspofungin Available for second line use on the approval of a consultant microbiologist CASPOFUNGIN 5.2 Antifungal drugs->5.2.4 Echinocandin antifungals Available for second line use on the approval of a consultant microbiologist CEFOTAXIME Cephalosporins For treatment of bacterial meningitis and meningococcal septicaemia. See Trust Antibiotic Policy Cefotaxime Cephalosporins->CEFOTAXIME For treatment of bacterial meningitis and meningococcal septicaemia. See Trust Antibiotic Policy CEFTAZIDIME Cephalosporins To be used in accordance with Febrile Neutropenia Guideline (DA-005). See Trust Antibiotic Policy Ceftazidime Cephalosporins->CEFTAZIDIME To be used in accordance with Febrile Neutropenia Guideline (DA-005). See Trust Antibiotic Policy CEFTRIAXONE Cephalosporins For the treatment of bacterial meningitis, meningococcal septicaemia and treatment of gonorrhoea. See Trust Antibiotic Policy
10 Ceftriaxone Cephalosporins->CEFTRIAXONE For the treatment of bacterial meningitis, meningococcal septicaemia and treatment of gonorrhoea. See Trust Antibiotic Policy Chloramphenicol antibacterials For bacterial meningitis in patients with a history of penicillin or cephalosporin anaphylaxis. See Trust Antibiotic Guidelines. CHLORAMPHENICOL antibacterials->chloramphenicol For bacterial meningitis in patients with a history of penicillin or cephalosporin anaphylaxis. See Trust Antibiotic Guidelines. CIPROFLOXACIN 5.1 Antibacterial drugs-> Quinolones Consultant approval required. Ciprofloxacin 5.1 Antibacterial drugs-> Quinolones->CIPROFLOXACIN Consultant approval required. Ciproxin 5.1 Antibacterial drugs-> Quinolones->CIPROFLOXACIN Consultant approval required. CO-TRIMOXAZOLE 5.1 Antibacterial drugs->5.1.8 Sulfonamides and trimethoprim For treatment and prophylaxis of Pneumocystis carinii pneumonia (PCP). Co-trimoxazole 5.1 Antibacterial drugs->5.1.8 Sulfonamides and trimethoprim->co-trimoxazole For treatment and prophylaxis of Pneumocystis carinii pneumonia (PCP). Colomycin antibacterials->polymyxins->colistimethate SODIUM Available on agreement of antimicrobial pharmacist/microbiologist. For aerobic and anaerobic Gram +ve and Gram -ve infections resistant to other treatments Combined preparations drugs->rifampicin as part of combination treatment for TB DEMECLOCYCLINE HYDROCHLORIDE 5.1 Antibacterial drugs->5.1.3 Tetracyclines For inappropriate ADH secretion DIDANOSINE reverse transcriptase inhibitors Diflucan 5.2 Antifungal drugs->5.2.1 Triazole antifungals->fluconazole Consultant signature only unless iused in palliative care in which case a junoir doctor may sign but prescription must be countersigned by MacMillan nurse EFAVIRENZ 5.3 Antiviral drugs->5.3.1 HIV infection->non-nucleoside reverse transcriptase inhibitors Ethambutol drugs->ethambutol HYDROCHLORIDE as part of combination treatment for TB
11 ETHAMBUTOL HYDROCHLORIDE drugs as part of combination treatment for TB Fasigyn 5.1 Antibacterial drugs-> Metronidazole and tinidazole->tinidazole dr prestons signature only FLUCONAZOLE 5.2 Antifungal drugs->5.2.1 Triazole antifungals Consultant signature only unless when used in palliative care when a junior doctor may sign with a counter signature of a MacMillan Nurse Fortum Cephalosporins->CEFTAZIDIME To be used in accordance with Febrile Neutropenia Guideline (DA-005). See Trust Antibiotic Policy Fungizone 5.2 Antifungal drugs->5.2.3 Polyene antifungals->amphotericin Liposomal Amphoteracin (Ambisome)to be used in accordance with the febrile neutopenia guideline (DA-005)or as recommended by a haematologist/microbiologist. IMIPENEM WITH CILASTATIN carbapenems, and other beta-lactams-> Carbapenems Available on agreement of antimicrobial pharmacist/microbiologist. For aerobic and anaerobic Gram +ve and Gram -ve infections resistant to other treatments e.g. ESBL producing organisms. INDINAVIR 5.3 Antiviral drugs->5.3.1 HIV infection->protease inhibitors Invirase 5.3 Antiviral drugs->5.3.1 HIV infection->protease inhibitors->saquinavir Kefadim Cephalosporins->CEFTAZIDIME To be used in accordance with Febrile Neutropenia Guideline (DA-005). See Trust Antibiotic Policy LAMIVUDINE reverse transcriptase inhibitors LEVOFLOXACIN 5.1 Antibacterial drugs-> Quinolones for severe community acquired pneumonia in patients with definite history of penicillin or cephalosporin anaphylaxis Levofloxacin 5.1 Antibacterial drugs-> Quinolones->LEVOFLOXACIN for severe community acquired pneumonia in patients with definite history of penicillin or cephalosporin anaphylaxis Linezolid antibacterials Available on agreement of antimicrobial pharmacist/microbiologist. Activity against Gram +ve bacteria including MRSA and VRE. Full blood count should be monitored weekly during treatment. It should not be given with another monoamine oxidase inhibitor (MAOI)or within 2 weeks of stopping another MAOI. LINEZOLID antibacterials->linezolid Available on agreement of antimicrobial pharmacist/microbiologist. Activity against Gram +ve bacteria including MRSA and VRE. Full blood count should be monitored weekly during treatment. It should not be given with another monoamine oxidase inhibitor (MAOI)or within 2 weeks of stopping another MAOI.
12 LYMECYCLINE 5.1 Antibacterial drugs->5.1.3 Tetracyclines Lymecycline 5.1 Antibacterial drugs->5.1.3 Tetracyclines->LYMECYCLINE Meronem carbapenems, and other beta-lactams-> Carbapenems->MEROPENEM Available on agreement of antimicrobial pharmacist/microbiologist. For aerobic and anaerobic Gram +ve and Gram -ve infections resistant to other treatments MEROPENEM carbapenems, and other beta-lactams-> Carbapenems Available on agreement of antimicrobial pharmacist/microbiologist. For aerobic and anaerobic Gram +ve and Gram -ve infections resistant to other treatments NEVIRAPINE 5.3 Antiviral drugs->5.3.1 HIV infection->non-nucleoside reverse transcriptase inhibitors Non-nucleoside reverse transcriptase inhibitors Nucleoside reverse transcriptase inhibitors 5.3 Antiviral drugs->5.3.1 HIV infection 5.3 Antiviral drugs->5.3.1 HIV infection Use by Sexual Health Clinic only PALIVIZUMAB 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus Awaiting guidance on the use of this product from the Trust Chief Executive (D&T minutes 16th September 2002). PIPERACILLIN WITH TAZOBACTAM 5.1 Antibacterial drugs->5.1.1 Penicillins-> Antipseudomonal penicillins In accordance with the febrile neutropenia guideline (DA-005) and for hospital acquired pneumonia, hepatobiliary sepsis and severe septicaemia in accordance with Treatment of Infection guidelines Piperacillin with tazobactam 5.1 Antibacterial drugs->5.1.1 Penicillins-> Antipseudomonal penicillins->piperacillin WITH TAZOBACTAM In accordance with the febrile neutropenia guideline (DA-005) and for hospital acquired pneumonia, hepatobiliary sepsis and severe septicaemia in accordance with Treatment of Infection guidelines Primaxin carbapenems, and other beta-lactams-> Carbapenems->IMIPENEM WITH CILASTATIN Available on agreement of antimicrobial pharmacist/microbiologist. For aerobic and anaerobic Gram +ve and Gram -ve infections resistant to other treatments e.g. ESBL producing organisms. Promixin antibacterials->polymyxins->colistimethate SODIUM Available on agreement of antimicrobial pharmacist/microbiologist. For aerobic and anaerobic Gram +ve and Gram -ve infections resistant to other treatments Protease inhibitors 5.3 Antiviral drugs->5.3.1 HIV infection PYRAZINAMIDE drugs as part of combination treatment for TB Rifadin drugs->rifampicin Legionella infection and as part of combination treatment for TB
13 RIFAMPICIN drugs Legionella infection and as part of combination treatment for TB Rifampicin drugs->rifampicin Legionella infection and as part of combination treatment for TB Rimactane drugs->rifampicin Legionella infection and as part of combination treatment for TB RITONAVIR 5.3 Antiviral drugs->5.3.1 HIV infection->protease inhibitors Rocephin Cephalosporins->CEFTRIAXONE For the treatment of bacterial meningitis, meningococcal septicaemia and treatment of gonorrhoea. See Trust Antibiotic Policy SAQUINAVIR 5.3 Antiviral drugs->5.3.1 HIV infection->protease inhibitors Septrin 5.1 Antibacterial drugs->5.1.8 Sulfonamides and trimethoprim->co-trimoxazole For treatment and prophylaxis of Pneumocystis carinii pneumonia (PCP). STAVUDINE reverse transcriptase inhibitors Synagis 5.3 Antiviral drugs->5.3.5 Respiratory syncytial virus->palivizumab Awaiting guidance on the use of this product from the Trust Chief Executive (D&T Committee minute 16th September 2002). Targocid antibacterials->glycopeptides->teicoplanin First line glycopeptide used for MRSA infections and other infections caused by Gram +ve bacteria in accordance with the Treatment of Infection guidelines Tavanic 5.1 Antibacterial drugs-> Quinolones->LEVOFLOXACIN for severe community acquired pneumonia in patients with definite history of penicillin or cephalosporin anaphylaxis Tazocin 5.1 Antibacterial drugs->5.1.1 Penicillins-> Antipseudomonal penicillins->piperacillin WITH TAZOBACTAM In accordance with the febrile neutropenia guideline (DA-005) and for hospital acquired pneumonia, hepatobiliary sepsis and severe septicaemia in accordance with Treatment of Infection guidelines TEICOPLANIN antibacterials->glycopeptides First line glycopeptide used for MRSA infections and other infections caused by Gram +ve bacteria in accordance with the Treatment of Infection guidelines TERBINAFINE 5.2 Antifungal drugs->5.2.5 Other antifungals For dermatology use only Tetralysal Antibacterial drugs->5.1.3 Tetracyclines->LYMECYCLINE For dermatology use only
14 TINIDAZOLE 5.1 Antibacterial drugs-> Metronidazole and tinidazole Dr. Preston's signature only TINIDAZOLE 5.4 Antiprotozoal drugs->5.4.2 Amoebicides Dr. Preston\'s signature only Vancocin antibacterials->glycopeptides->vancomycin MRSA infection and other infections caused by Gram +ve bacteria in accordance with the Treatment of Infection guidelines. Requires close monitoring of plasma levels and renal function.oral - treatment of Clostridium difficle Infection. VANCOMYCIN antibacterials->glycopeptides MRSA infection and other infections caused by Gram +ve bacteria in accordance with the Treatment of Infection guidelines. Requires close monitoring of plasma levels and renal function. Oral- treatment of Clostridium difficile infection Vancomycin antibacterials->glycopeptides->vancomycin MRSA infection and other infections caused by Gram +ve bacteria in accordance with the Treatment of Infection guidelines. Requires close monitoring of plasma levels and renal function.. Oral - treatment of Clostridium difficile infection Vfend 5.2 Antifungal drugs->5.2.1 Triazole antifungals->voriconazole Available for second line use on the approval of a consultant microbiologist Viramune 5.3 Antiviral drugs->5.3.1 HIV infection->non-nucleoside reverse transcriptase inhibitors->nevirapine VORICONAZOLE 5.2 Antifungal drugs->5.2.1 Triazole antifungals Available for second line use on the approval of a consultant microbiologist ZIDOVUDINE reverse transcriptase inhibitors Use by Sexual Health Clinic only Zithromax 5.1 Antibacterial drugs->5.1.5 Macrolides->AZITHROMYCIN First line treatment for patients presenting to Department of Sexual Health. Available on consultant signature only for bronciectasis and cystic fibrosis patients.
5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
More informationChapter 5 ~ Infections
Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy
More informationCEFACLOR Non Formulary 5.1 Antibacterial drugs->5.1.2 Cephalosporins, carbapenems, and other beta-lactams-> Cephalosporins
Report generated from BNF - Local Information provided by FormularyComplete (www.pharmpress.com). Accessed 31 07 2017 Title Formulary Status Section Amikacin Non Formulary 5.1 Antibacterial drugs->5.1.4
More informationNHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections
1 5. Infections Also see Primary Care and Hospital Antibiotic Guidance NHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections Management of Serious Infections in Paediatrics. Guidance
More informationgram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium
Mickey Dufilho s Drugs and Bugs Revised 10/10/15 Bacteria Drugs that Inhibit Cell Wall Synthesis Drug Action Spectrum of Action Comments Spectrum of Action Bacitracin Beta-Lactam antibiotics Penicillin
More informationThis letter authorises the extended use of the following guidance until 1st December 2018:
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 1h May 2018 Our Ref FApenicillin/hype/MGPG/May 18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224
More informationChapter 5 Infections
Chapter 5 page number 1 Chapter 5 Infections First line drugs Drugs recommended in both primary and secondary care. Second line drugs Alternatives (often in specific conditions) in both primary and secondary
More informationB. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.
Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01
More informationInventory of paediatric therapeutic needs
12 December 2012 EMA/PDCO/287222/2012 Human Medicines Development and Evaluation Infectious diseases Agreed by PDCO November 2012 Adopted by PDCO for release for consultation 7 December 2012 Start of public
More informationDrug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD
Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal
More informationHospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing
Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Infections therapeutic group PTAC and Subcommittee of PTAC minutes are
More informationBoth adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationDrug Classification and Pharmacologic Actions
Drug Classification and Pharmacologic Actions Learning Outcomes For major classes of drugs: Identify common drug names for each classification Describe actions- therapeutic uses Describe most common or
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More information2019 PHP PRIMARY CARE INCENTIVE
Primary Care Physicians (PCP) of Physicians Health Network (PHN) may be eligible for an incentive payment in accordance with this PHP PCP Incentive (hereinafter referred to as the PCP Incentive ). As described
More informationOrchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department
Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Dr. Eugene Tso Division of Infectious Diseases Department of Medicine & Geriatrics United Christian Hospital 11 May 2010
More informationLifting the lid on a difficile problem part 2 (Clinical) Evidence Based Practice. Problem in evolution (1) Problem in evolution (1) Interventions (2)
Lifting the lid on a difficile problem part (Clinical) Dr Philip T Mannion Consultant Microbiologist, Rhyl Evidence Based Practice Antibiotic prescribing guidance Isolation policy Hand hygiene (soap and
More informationFraser Health pandemic preparedness
Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More information104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationREIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationUPDATE ON FEBRILE NEUTROPENIA
UPDATE ON FEBRILE NEUTROPENIA Clinical approach and management Dr.Shafiq A. Alimad Head of medical department at university of science and technology hospital YICID 15-December-2014 INTRODUCTION Cancer
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin
More informationMONTEFIORE MEDICAL CENTER
DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September
More informationInfection. Chapter 5 TABLE OF CONTENTS
Chapter 5 Infection TABLE OF CONTENTS Table of Contents... 1 1 Antibacterial Drugs... 2 1.1 Before starting therapy... 2 1.1.1 Pregnancy... 2 1.1.2 Renal impairment... 2 1.2 Aminoglycosides... 2 1.2.1
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationShirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate
Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC
More informationAdult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More information1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
More informationPOLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin
More informationEFFECT OF ANTIMICROBIAL DRUGS ON THE INTESTINAL MICROFLORA: IMPORTANCE OF PHARMACOKINETIC PROPERTIES OF ANTIBACTERIAL AGENTS TOM BERGAN
Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and
More informationAppendix 4: Renal impairment
Appendix 4: Renal impairment Reduced renal function may cause problems with drug therapy for the following reasons: 1. The failure to excrete a drug or its metabolites may produce toxicity. 2. The to some
More informationADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017)
(NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Introduction The dosing recommendations presented here are for adults with moderate-to-severe infections and are
More informationGUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition
ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE GUIDELINES FOR USERS 17th Edition 2011 Earlier editions should be destroyed Antimicrobial Reference Laboratory Department of Medical Microbiology North
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationCommunity Pharmacy Support Guidance: Electronic Repeat Dispensing (erd)
Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd) Version: 2.1 Date Published October 2018 Author: Rachel Raybould, Midland and Lancashire CSU 1 Introduction: Welcome to the Community
More informationRed Book : Errata. (Revised 12/15/03)
Red Book : 2003 REPORT OF THE COMMITTEE ON INFECTIOUS DISEASES Errata (Revised 12/15/03) For the most up-to-date list of important Red Book errata, please visit the Red Book Online Web site at http://www.aapredbook.org.
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS
ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence
More informationFORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary
At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors
More informationAntimicrobials; antibacterials, antifungals, antiprotozoans, antivirals, and antihelminthics 6
Antimicrobials; antibacterials, antifungals, antiprotozoans, antivirals, and antihelminthics 6 Inhibition of Ergosterol Synthesis Azoles Miconazole Triazoles Allylamines For azole-resistant infections
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationBUGS and DRUGS Part 2 March 13, 2013 Marieke Kruidering- Hall
BUGS and DRUGS Part March, 0 Marieke Kruidering- Hall BIOGRAPHY: Marieke Kruidering- Hall is Associate Professor in the Department of Cellular & Molecular Pharmacology. She was born in the Netherlands.
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides
More informationAntiretroviral Nucleoside reverse transcriptase inhibitor (NRTI)
1 2004-2005 Respiratory Review 2 Abacavir Nucleoside reverse transcriptase inhibitor (NRTI) 3 Acebutolol β 1 adrenergic antagonist Class II antiarrhythmic Antianginal 4 Albuterol β 2 adrenergic agonist
More informationAetiology Viruses are the most common cause of meningitis, and are often less serious than bacterial or fungal forms of the disease.
Infective meningitis is an inflammation of the arachnoid and pia mater associated with the presence of bacteria, viruses, fungi or protozoa in the CSF. Meningitis is associated with significant mortality
More informationMonographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
More informationOPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY. BSAC OPAT REGIONAL WORKSHOP London 14 May 2018
OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY BSAC OPAT REGIONAL WORKSHOP London 14 May 2018 Presented by Felicity Drummond Senior Project Manager, BSAC NORS provides the most
More informationCURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
More information1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
More informationArkansas Blue Cross and Blue Shield Metallic Formulary List of Covered Drugs
Arkansas Blue Cross and Blue Shield Metallic Formulary 2018 List of Covered Drugs PLEASE READ: THIS DOCUMENT HAS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Members must use network pharmacies to
More informationArkansas Blue Cross and Blue Shield Metallic Formulary List of Covered Drugs
Arkansas Blue Cross and Blue Shield Metallic Formulary 2018 List of Covered Drugs PLEASE READ: THIS DOCUMENT HAS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Members must use network pharmacies to
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationArkansas Blue Cross and Blue Shield Metallic Formulary List of Covered Drugs
Arkansas Blue Cross and Blue Shield Metallic Formulary 2018 List of Covered Drugs PLEASE READ: THIS DOCUMENT HAS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Members must use network pharmacies to
More informationOPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry
OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry For enquiries/support: Service Directory in Action! Can BSAC sort out daily antibiotics? GP R OPAT Community and
More informationPOLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF UPPER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: Date: July 2018 The Drugs & Therapeutics Committee Implementation
More informationCritical Time Medication Procedure
Ref:PharmMM74 Critical Time Medication Procedure INITIATED BY: APPROVED BY: DATE APPROVED: Suzanne Scott-Thomas, Amanda Halloway Endorsed by Medication Safety Committee Sept 2011 VERSION: 1.1 OPERATIONAL
More informationDrug Class Review Monograph GPI Class 12 Antivirals
Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,
More informationVIII Updating Course of Antimicrobials and Infectious Diseases 2018
The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
More informationMedicinal Chemistry 410 Exam #1 February 20, 2009 Name: Med. Chem. #
Medicinal Chemistry 410 Exam #1 February 20, 2009 ame: Med. Chem. # 1 Part. (75 Points) There are 50 multiple choice questions worth 1.5 points each (75 Points). Please use the cantron heet provided. f
More informationRecommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationSection H: Treatments
TIME THIS SECTION BEGINS RECORDED HERE TSST04H Section H: Treatments H1. Have you ever taken AZT, a protease inhibitor, or any other drugs such as those listed on this card to treat your HIV infection
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationSUPPLEMENT ARTICLE DEFINITIONS
SUPPLEMENT ARTICLE The Infectious Diseases Society of America 2002 Guidelines for the Use of Antimicrobial Agents in Patients with Cancer and Neutropenia: Salient Features and Comments Kenneth V. I. Rolston
More informationKentucky Department for Medicaid Services. Drug Review Options
Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the November 21, 2013 meeting of the Pharmacy
More informationArkansas Blue Cross and Blue Shield Metallic Formulary List of Covered Drugs
Arkansas Blue Cross and Blue Shield Metallic Formulary 018 List of Covered Drugs PLEASE READ: THIS DOCUMENT HAS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Members must use network pharmacies to
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationArkansas Blue Cross and Blue Shield Metallic Formulary List of Covered Drugs
Arkansas Blue Cross and Blue Shield Metallic Formulary 2018 List of Covered Drugs PLEASE READ: THIS DOCUMENT HAS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Members must use network pharmacies to
More informationAntibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin
Antibiotic Class Interacting Drug Comment Penicillins Methotrexate Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Cephalosporins Cefaclor Cefixime Cefuroxime Cephalexin Cefazolin* Ceftriaxone*
More informationClinical Pearls Infectious Diseases. Pritish K. Tosh, MD MN ACP Nov 7, [Answers and discussion slides will be posted after the meeting]
Clinical Pearls Infectious Diseases Pritish K. Tosh, MD MN ACP Nov 7, 2014 [Answers and discussion slides will be posted after the meeting] Case 1 A 33-year-old male with diffuse large B-cell lymphoma
More informationHIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT)
HIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT) 2/21/2014 HIV STATISTICS IN SOUTH AFRICA One in every 10
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationDrug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
More informationCondition Major Pathogens First Choice Therapy Alternative Therapy Comments. Clinically stable: Clindamycin 13mg/kg/dose IV q8h (max 900mg/dose)
BONE JOINT INFECTIONS... 1 CNS INFECTIONS... 2 GASTROINTESTINAL INFECTIONS... 3 FEVER IN ONCOLOGY BMT PATIENTS... 4 FEVER WITHOUT A SOURCE, YOUNG INFANT... 5 HEAD NECK INFECTIONS... 6 INTRA-ABDOMINAL INFECTIONS...
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationMCQ S. 1. Which of the following could be given to someone who had an allergy to sulphonamides previously:
MCQ S 1. Which of the following could be given to someone who had an allergy to sulphonamides previously: a) Acetazolamide b) Frusemide c) Bumetanide d) Pyrimethamine e) Diazoxide 2. Which of the following
More informationWORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation
Practical Pointers pointers For for Your your Practice practice The Multiple Facets of CAP Dr. George Fox, MD, MSc, FRCPC, FCCP Community acquired pneumonia (CAP) continues to be a significant health burden
More informationBlue MedicareRx SM Premier (PDP) 2018 Formulary (List of Covered Drugs)
Blue MedicareRx SM Premier (PDP) 2018 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 07/01/2018. For
More informationThe Epidemiology of Candidaemia in Northern Ireland
The Epidemiology of Candidaemia in Northern Ireland 2001-2011 November 2013 1 Executive Summary In Northern Ireland (NI), over the last decade, the analysis of trends from voluntarily reported laboratory
More informationAntibiotic Dosing in the Elderly
Antibiotic Dosing in the Elderly Philip Chung, PharmD, MS, BCPS Nebraska ASAP Community Network Pharmacy Coordinator Nebraska Medicine Disclosure I have no relevant disclosure The presentation includes
More informationMedication Guide. October Contents. Preferred Medication List
October 08 Medication Guide Please consider talking to your doctor about prescribing one of the formulary medications that are indicated as covered under your plan; which may help reduce your out-of-pocket
More informationI is a cascading prodrug. II is used to treat hepatitis B infection III ultimately inhibits viral reverse transcriptase.
Medicinal Chemistry 410 Exam #1 February 19, 2010 ame: Med. Chem. # 1 Part. (75 Points) There are 50 multiple choice questions worth 1.5 points each (75 Points). Please use the cantron heet provided. f
More informationAntibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013
Antibiotic Consumption in the Community in Ireland REPORT FOR First Half of 2013 1 Summary: Community Antibiotic Use The rate for Quarter 1 of 2013 (1 st January to 31 st March) was 27.4 Defined Daily
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationAntifungals, antivirals, antiprotozoals, and anthelmintics
Antifungals, antivirals, antiprotozoals, and anthelmintics Joseph K. Ritter, PhD Asst. Prof Department of Pharmacology and Toxicology MSB Room 530 jritter@hsc.vcu.edu Difficulties associated with treatment
More informationHealth Insurance Marketplace 6 Tier Drug List
January 09 Health Insurance Marketplace 6 Tier Drug List Please consider talking to your doctor about prescribing preferred medications, which may help reduce your out-of-pocket costs. This list may help
More informationAlabama Medicaid Pharmacist
Alabama Medicaid Pharmacist Published Quarterly by Health Information Designs, LLC, Winter 015 edition A Service of Alabama Medicaid PDL Update Effective January 5, 015, the Alabama Medicaid Agency will
More informationIV 5 mg/kg q12h 5 mg/kg q24h 2.5 mg/kg q24h mg/kg q24h (post HD) 50% standard dose q24h 5 mg/kg q24h. IV 5-10 mg/kg q12h
Page 1 of 18 male: = (140-Age) IBW Drug Name Usual Dose (Normal Renal Function) CrCl (ml/min) Dose Adjustment (In renal insufficiency) Acyclovir (Zovirax) *Use IBW Mucosal & cutaneous IV: 5 mg/kg q8h PO:
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationFORMULARY. (List of Covered Drugs) Molina Dual Options MyCare Ohio (Medicare-Medicaid Plan)
FORMULARY (List of Covered Drugs) 2015 Molina Dual Options MyCare Ohio (Medicare-Medicaid Plan) Version 14 UPDATED: 11/2015 Member Services (855) 665-4623, TTY/TDD 711 Monday - Friday, 8 a.m. - 8 p.m.
More information